Ono Pharmaceutical (OTCMKTS:OPHLF) Trading Up 9.2% – What’s Next?

Ono Pharmaceutical Co. (OTCMKTS:OPHLF)’s share price was up 9.2% during mid-day trading on Monday . The stock traded as high as $14.61 and last traded at $14.61. Approximately 212 shares were traded during trading, a decline of 52% from the average session volume of 438 shares. The stock had previously closed at $13.38.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded shares of Ono Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, According to MarketBeat, the company has a consensus rating of “Strong Buy”.

Ono Pharmaceutical Price Performance

The stock’s fifty day moving average price is $14.33 and its 200-day moving average price is $14.76. The firm has a market cap of $6.87 billion, a PE ratio of 14.76 and a beta of 0.34. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.02 and a quick ratio of 2.56.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.